ELAB — Elevai Labs, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology
$5.08
+$0.05 (+0.99%)
Elevai Labs, Inc. Common Stock (ELAB) is a biotechnology company listed on NASDAQ. It is led by Graydon Bensler C.F.A., based in 120 Newport Center Drive, Newport Beach, CA, United States, 92660, with about 32 employees. PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Latest reported ELAB revenue for 2025-09-30 was $285.9K. Net income was -$2.6M. ELAB currently screens at market cap $6.5M.
Use this ELAB page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ELAB quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ELAB SEC filings page. Lician reads the product cache first so this HTML stays unique to Elevai Labs, Inc. Common Stock even when a live quote feed is slow.
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
ELAB Key Statistics
Market Cap
$6.50M
Volume
44,549
Previous Close
$5.69
Day Range
$5.59 – $6.20
P/B Ratio
0.52
EPS
$0.00
Revenue
$0.00
Net Income
-$6.25M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
32
ELAB Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $1.71M | $766.28K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$6.25M | -$4.30M | -$1.80M |
| EPS (Diluted) | $0.00 | -$0.40 | -$0.19 |
Total Assets
$8.99M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.98M
Operating Cash Flow
-$5.49M
Free Cash Flow
$0.00
Elevai Labs, Inc. Common Stock Company Information
- CEO, CFO, Secretary & Director
- Graydon Bensler C.F.A.
- Headquarters
- 120 Newport Center Drive, Newport Beach, CA, United States, 92660
- Website
- pmgcholdings.com
- Phone
- 866 445 4886
- IPO / Founded
- 2023-11-21
- Sector
- Healthcare
- Industry
- Biotechnology